{
    "nctId": "NCT05549024",
    "briefTitle": "68Ga-RM26-RGD PET/CT Imaging in the GRPR and \u03b1v\u03b23 Positive Tumor Patients",
    "officialTitle": "68Ga-RM26-RGD PET/CT Imaging in the GRPR and \u03b1v\u03b23 Positive Tumor Patients",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Prostate Cancer, Brain Tumor, PET/CT Imaging",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 90,
    "primaryOutcomeMeasure": "Diagnostic performance1",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* patients with confirmed or suspected breast/brain/prostate cancer;\n* 68Ga-RM26-RGD and 18F-FDG(or 68Ga-RM26 or 68Ga-RGD) PET/CT within 2 week;\n* signed written consent.\n\nExclusion Criteria:\n\n* pregnancy;\n* breastfeeding;\n* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}